Skip to main content
Fuan Pharmaceutical （Group）co.,Ltd logo

Fuan Pharmaceutical （Group）co.,Ltd — Investor Relations & Filings

Ticker · 300194 ISIN · CNE1000011G4 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,013 across all filing types
Latest filing 2022-09-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300194

About Fuan Pharmaceutical （Group）co.,Ltd

https://www.fapharm.com

Fuan Pharmaceutical (Group) Co., Ltd. is an integrated pharmaceutical enterprise specializing in the research, development, production, and distribution of a wide range of chemical drugs. The company operates across the entire value chain, encompassing pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage forms. Its product portfolio primarily focuses on anti-infectives, particularly cephalosporins and penicillins, as well as treatments for cardiovascular diseases, oncology, and respiratory conditions. Fuan Pharmaceutical maintains large-scale manufacturing facilities and emphasizes technological innovation to support its diverse pipeline of generic and specialized medications. The group serves both domestic and international markets, providing essential healthcare solutions through its network of subsidiaries and specialized production bases.

Recent filings

Filing Released Lang Actions
关于注射用头孢呋辛钠通过仿制药质量和疗效一致性评价的公告(1)
Regulatory Filings Classification · 95% confidence The document is a short announcement (644 characters) from a company about its subsidiary receiving an approval notice from the National Medical Products Administration regarding a drug supplement application. It contains no financial data, no detailed report, and no mention of a report being attached or published. It is an official announcement about regulatory approval related to the company's product, not a financial report or management information. This fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-09-07 Chinese
2022年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 90% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the first half of 2022, prepared by the company 福安药业（集团）股份有限公司. It contains specific financial data such as balances, amounts occupied, interest, repayments, and relationships with related parties. The document length is 2521 characters, which is relatively short but contains substantive financial data and analysis for a half-year period. The content is consistent with a financial report covering a period shorter than a full fiscal year, specifically a semi-annual report. There is no indication that this is merely an announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-29 Chinese
关于为子公司申请银行授信融资提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 福安药业（集团）股份有限公司 regarding the provision of guarantees for bank credit financing applied for by its subsidiaries. It details the guarantee amounts, involved parties, financial data of the subsidiaries, and approvals from the board and independent directors. The content focuses on financing guarantees and related approvals rather than financial results, management changes, or legal proceedings. It is not a full financial report, earnings release, or management discussion. The document is a formal announcement about capital/financing activities, specifically guarantees related to bank credit financing. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3402 characters, which is consistent with an announcement rather than a full report.
2022-08-29 Chinese
2022年半年度报告披露提示性公告
Report Publication Announcement Classification · 100% confidence The document is a short announcement (295 characters) stating that the company's 2022 half-year report will be disclosed on a specified date and website. It does not contain the actual half-year financial report or substantive financial data, but merely informs investors about the upcoming report publication. According to the 'MENU VS MEAL' rule, such a brief notice about report availability is classified as a Report Publication Announcement (RPA), not as the Interim/Quarterly Report (IR) itself.
2022-08-29 Chinese
关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding a change in accounting policies by the company 福安药业（集团）股份有限公司. It details the reasons for the change, the new accounting policies adopted, the date of change, and the approvals by the board and independent directors. It does not contain financial statements or detailed financial performance data but rather explains the policy change and its impact. The document length is 2307 characters, which is relatively short and reads like an official announcement rather than a full report. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2022-08-29 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of the company 福安药业 (Fuan Pharmaceutical Group) regarding their meeting held on August 29, 2022. It includes approval of the 2022 semi-annual report and its summary, changes in accounting policies, and approval for guarantees for bank credit financing for subsidiaries. The document is short (1002 characters) and primarily announces decisions made by the Supervisory Board rather than containing the full semi-annual report or detailed financial data. It also references that the detailed announcement about the guarantee is published elsewhere. This fits the profile of a Regulatory Filing (RNS) as it is a formal announcement of board resolutions and approvals without substantive financial statements or detailed report content. It is not the full Interim/Quarterly Report (IR) itself, nor an Annual Report (10-K), nor a Management Report (MDA).
2022-08-29 Chinese

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.